Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 13/20 | 1.00 |
| ▸ | HCAR3 | P49019 | 3/20 | 1.00 |
| ▸ | DAO | P14920 | 1/20 | 0.57 |
| ▸ | CYTH3 | O43739 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | EPN1 | Q9Y6I3 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31467457 | 0.98 | HCAR2 (0.96) | HCAR2HCAR3DAOCYTH3BTK | |
| SCHEMBL5599627 | 0.86 | HCAR2 (0.76) | HCAR2HCAR3DAOCYTH3BTK | |
| SCHEMBL15253861 | 0.86 | HCAR3 (0.75) | HCAR2HCAR3MAPTNPC1RAB9A | |
| SCHEMBL15116888 | 0.84 | HCAR3 (0.72) | HCAR2HCAR3MAPTNPC1RAB9A | |
| SCHEMBL19924463 | 0.82 | HCAR3 (0.70) | HCAR2HCAR3MAPTNPC1RAB9A | |
| SCHEMBL5599868 | 0.82 | HCAR2 (0.69) | HCAR2HCAR3DAOCYTH3BTK | |
| SCHEMBL5599290 | 0.82 | HCAR2 (0.69) | HCAR2HCAR3DAOCYTH3BTK | |
| SCHEMBL5599520 | 0.82 | HCAR2 (0.69) | HCAR2HCAR3DAOCYTH3BTK | |
| SCHEMBL19646366 | 0.80 | HCAR2 (0.64) | HCAR2HCAR3DAOMAPTNPC1 | |
| SCHEMBL2763093 | 0.80 | HCAR2 (0.67) | HCAR2HCAR3DAOCYTH3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56073024-A | — | — | None | — | — | JP | disclosed |
| US-20250214984-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-07-03 | — | — | US | disclosed |
| EP-4146645-B1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025096657-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096653-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096660-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096654-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096658-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096662-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12269817-B2 | Compound having KDM5 inhibitory activity and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-04-08 | — | — | US | disclosed |
| EP-1444009-A1 | TREATMENT OF INSULIN RESISTANCE SYNDROME AND TYPE 2 DIABETES WITH PDE9 INHIBITORS | Pfizer Products Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-1440073-A1 | PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS | Pfizer Limited (GB) | 2004-07-28 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | FRYBURG DAVID A (US) | 2004-02-05 | — | — | US | disclosed |
| US-20030195205-A1 | PDE9 inhibitors for treating cardiovascular disorders | PFIZER INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003037899-A1 | PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS | PFIZER LIMITED (GB) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003037432-A1 | TREATMENT OF INSULIN RESISTANCE SYNDROME AND TYPE 2 DIABETES WITH PDE9 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
| JP-S5673024-A | ANTIHYPERLIPEMIC AGENT | MORISHITA SEIYAKU KK | 1981-06-17 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | HCAR2 3979/4885HCAR3 3436/4885DAO 1381/4885 |
| US-12269817-B2 | Compound having KDM5 inhibitory activity and pharmaceutical use thereof | KDM5A, KDM5B, KDM5D | HCAR2 1733/4885HCAR3 2210/4885DAO 3429/4885 |
| US-20030195205-A1 | PDE9 inhibitors for treating cardiovascular disorders | PDE9A, PDE2A, PDE3A | HCAR2 147/4885HCAR3 316/4885DAO 982/4885 |
| US-20250214984-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | KDM5A, KDM5B, KDM5D | HCAR2 1733/4885HCAR3 2210/4885DAO 3429/4885 |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | HCAR2 1033/4885HCAR3 2113/4885DAO 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.